Skip to content

Uterine Cervix repeated Magnetic Resonance Imaging for adaptive treatment planning of cervical cancer radiotherapy. A single-center study

Uterine Cervix repeated Magnetic Resonance Imaging for adaptive treatment planning of cervical cancer radiotherapy. A single-center study - CeReMony

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42497
Enrollment
20
Registered
2015-11-12
Start date
2016-05-25
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Clinical indication for chemoradiotherapy with curative intent (one of the following): -FIGO [1] stage IA, IB1 or IIA1 cervical cancer with regional lymph node pathology, -FIGO stage IA, IB1 or IIA1 cervical cancer with contraindications for surgery -FIGO stage IB2, IIA2, IIB, IIIA, IIIB, or IVA cervical cancer * Medical condition that allows chemoradiotherapy with curative intent * Age * 18 years * Signed informed consent, obtained before the acquisition of the first additional MRI scan * Able to comply with the variable bladder filling protocol (drinking and voiding instructions, this protocol is part of standard clinical care)

Exclusion criteria

Exclusion criteria: * Patients who meet exclusion criteria for MRI at 1.5T following the protocol of the department of Radiology of the UMC Utrecht * Patients who are mentally or otherwise disabled and/or considered legally incapable * History of previous pelvic radiotherapy * Pregnant or breast-feeding patients

Design outcomes

Primary

MeasureTime frame
We will develop a new workflow for MRI-guided adaptive radiotherapy, assessing the accuracy of semi-automatic delineation of target volume and critical organs. Treatment remains according to standard clinical practice, but we will (digitally) simulate our new workflow using the acquired MRI scans.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)